Bio-Gene Technology (ASX: $BGT) Q4 FY24 activities update

Bio-Gene Technology Limited (BGT) provides an update on its activities for the quarter ended 30 June 2024 (Q4 FY24) and to date, alongside the Company's Appendix 4C. The company has made significant progress in product evaluation, formulation development, and completion of the twelfth Qcide harvest, aiming to support future commercialization.

CEO & Managing Director, Tim Grogan, on Q4 FY24 progress

We have had a strong quarter progressing our busy program of work for the scale-up and regulatory requirements of our two flagship products, Flavocide and Qcide. Our formulation development programs have evolved to optimize the effectiveness of Qcide and Flavocide and provide benefits for future commercial partners. These formulations are being developed with input from highly experienced formulation technology specialists in Australia and the US. Product evaluation by our commercial partners continues to demonstrate the performance of our products, for example, in mosquito control. Once approved by regulators, the impact our products will have on public health around the world is significant.

Bio-Gene Technology (ASX: $BGT) Q4 FY24 activities summary

Bio-Gene Technology (BGT) has made significant advancements in the formulation development and completion of the twelfth Qcide harvest. The company's focus on scale-up manufacturing and regulatory-enabling studies for Flavocide and Qcide positions it strongly to generate value from its key products. The new modes of action of Flavocide and Qcide present Bio-Gene with a powerful strategic position in the target insecticide markets of agriculture, public health, and consumer products. The company continues to engage with multiple commercial partners to bring these products to market, aiming to offer safe and effective solutions to combat mosquitoes and other carriers of vector-borne diseases.